These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31283931)

  • 1. Olesoxime in neurodegenerative diseases: Scrutinising a promising drug candidate.
    Weber JJ; Clemensson LE; Schiöth HB; Nguyen HP
    Biochem Pharmacol; 2019 Oct; 168():305-318. PubMed ID: 31283931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat.
    Clemens LE; Weber JJ; Wlodkowski TT; Yu-Taeger L; Michaud M; Calaminus C; Eckert SH; Gaca J; Weiss A; Magg JC; Jansson EK; Eckert GP; Pichler BJ; Bordet T; Pruss RM; Riess O; Nguyen HP
    Brain; 2015 Dec; 138(Pt 12):3632-53. PubMed ID: 26490331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olesoxime, a cholesterol-like neuroprotectant for the potential treatment of amyotrophic lateral sclerosis.
    Martin LJ
    IDrugs; 2010 Aug; 13(8):568-80. PubMed ID: 20721828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The calpain-suppressing effects of olesoxime in Huntington's disease.
    Weber JJ; Ortiz Rios MM; Riess O; Clemens LE; Nguyen HP
    Rare Dis; 2016; 4(1):e1153778. PubMed ID: 27141414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitochondrial membrane fluidity is consistently increased in different models of Huntington disease: restorative effects of olesoxime.
    Eckmann J; Clemens LE; Eckert SH; Hagl S; Yu-Taeger L; Bordet T; Pruss RM; Muller WE; Leuner K; Nguyen HP; Eckert GP
    Mol Neurobiol; 2014 Aug; 50(1):107-18. PubMed ID: 24633813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olesoxime (TRO19622): A Novel Mitochondrial-Targeted Neuroprotective Compound.
    Bordet T; Berna P; Abitbol JL; Pruss RM
    Pharmaceuticals (Basel); 2010 Jan; 3(2):345-368. PubMed ID: 27713255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olesoxime, a cholesterol-like neuroprotectant restrains synaptic vesicle exocytosis in the mice motor nerve terminals: Possible role of VDACs.
    Zakyrjanova GF; Gilmutdinov AI; Tsentsevitsky AN; Petrov AM
    Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Sep; 1865(9):158739. PubMed ID: 32428575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting putative components of the mitochondrial permeability transition pore for novel therapeutics.
    Winquist RJ; Gribkoff VK
    Biochem Pharmacol; 2020 Jul; 177():113995. PubMed ID: 32339494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis.
    Lenglet T; Lacomblez L; Abitbol JL; Ludolph A; Mora JS; Robberecht W; Shaw PJ; Pruss RM; Cuvier V; Meininger V;
    Eur J Neurol; 2014 Mar; 21(3):529-36. PubMed ID: 24447620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis.
    Bordet T; Buisson B; Michaud M; Drouot C; Galéa P; Delaage P; Akentieva NP; Evers AS; Covey DF; Ostuni MA; Lacapère JJ; Massaad C; Schumacher M; Steidl EM; Maux D; Delaage M; Henderson CE; Pruss RM
    J Pharmacol Exp Ther; 2007 Aug; 322(2):709-20. PubMed ID: 17496168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olesoxime delays muscle denervation, astrogliosis, microglial activation and motoneuron death in an ALS mouse model.
    Sunyach C; Michaud M; Arnoux T; Bernard-Marissal N; Aebischer J; Latyszenok V; Gouarné C; Raoul C; Pruss RM; Bordet T; Pettmann B
    Neuropharmacology; 2012 Jun; 62(7):2346-52. PubMed ID: 22369784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial.
    Bertini E; Dessaud E; Mercuri E; Muntoni F; Kirschner J; Reid C; Lusakowska A; Comi GP; Cuisset JM; Abitbol JL; Scherrer B; Ducray PS; Buchbjerg J; Vianna E; van der Pol WL; Vuillerot C; Blaettler T; Fontoura P;
    Lancet Neurol; 2017 Jul; 16(7):513-522. PubMed ID: 28460889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olesoxime (cholest-4-en-3-one, oxime): analgesic and neuroprotective effects in a rat model of painful peripheral neuropathy produced by the chemotherapeutic agent, paclitaxel.
    Xiao WH; Zheng FY; Bennett GJ; Bordet T; Pruss RM
    Pain; 2009 Dec; 147(1-3):202-9. PubMed ID: 19833436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olesoxime favors oligodendrocyte differentiation through a functional interplay between mitochondria and microtubules.
    Magalon K; Le Grand M; El Waly B; Moulis M; Pruss R; Bordet T; Cayre M; Belenguer P; Carré M; Durbec P
    Neuropharmacology; 2016 Dec; 111():293-303. PubMed ID: 27618742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular mechanism of olesoxime-mediated neuroprotection through targeting α-synuclein interaction with mitochondrial VDAC.
    Rovini A; Gurnev PA; Beilina A; Queralt-Martín M; Rosencrans W; Cookson MR; Bezrukov SM; Rostovtseva TK
    Cell Mol Life Sci; 2020 Sep; 77(18):3611-3626. PubMed ID: 31760463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olesoxime prevents microtubule-targeting drug neurotoxicity: selective preservation of EB comets in differentiated neuronal cells.
    Rovini A; Carré M; Bordet T; Pruss RM; Braguer D
    Biochem Pharmacol; 2010 Sep; 80(6):884-94. PubMed ID: 20417191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olesoxime protects embryonic cortical neurons from camptothecin intoxication by a mechanism distinct from BDNF.
    Gouarné C; Giraudon-Paoli M; Seimandi M; Biscarrat C; Tardif G; Pruss RM; Bordet T
    Br J Pharmacol; 2013 Apr; 168(8):1975-88. PubMed ID: 23278424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nortriptyline delays disease onset in models of chronic neurodegeneration.
    Wang H; Guan Y; Wang X; Smith K; Cormier K; Zhu S; Stavrovskaya IG; Huo C; Ferrante RJ; Kristal BS; Friedlander RM
    Eur J Neurosci; 2007 Aug; 26(3):633-41. PubMed ID: 17686041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective role of olesoxime against wild-type α-synuclein-induced toxicity in human neuronally differentiated SHSY-5Y cells.
    Gouarné C; Tracz J; Paoli MG; Deluca V; Seimandi M; Tardif G; Xilouri M; Stefanis L; Bordet T; Pruss RM
    Br J Pharmacol; 2015 Jan; 172(1):235-45. PubMed ID: 25220617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitochondria-targeted peptide antioxidants: novel neuroprotective agents.
    Szeto HH
    AAPS J; 2006 Aug; 8(3):E521-31. PubMed ID: 17025271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.